Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
By association a possible mechanism
2022-02-08

By association, a possible mechanism which may underlie the progression of seizures is long-term potentiation (LTP). Indeed, LTP shares many common mechanisms with seizures activity both anatomically and physiologically, and has been implicated as a mechanism of acute epileptogenesis (Wasterlain et
-
Compound and several additional FPR antagonists identified
2022-02-08

Compound 10 and several additional FPR1 antagonists identified here specifically blocked fMLF-induced responses mediated via FPR1 in FPR1-HL60 TAPI-1 and human neutrophils, but not responses mediated via FPR2 or FPR3 (in human neutrophils and transfected HL60 cells) or Fpr1 (murine neutrophils and t
-
(-)-p-Bromotetramisole Oxalate australia We next investigate
2022-02-08

We next investigated whether pharmaceutical inhibition of the PI3K pathway was synergistic with FGFR inhibition using BKM120, a pan-PI3K inhibitor with modest antitumor activity in cancer patients, as a single agent. We found that RT112 (- translocation) and JMSU1 ( amplification) were not signifi
-
br Declarations of interest br Founding information This wor
2022-02-08

Declarations of interest Founding information This work was partially supported by the New Energy and Industrial Technology Development Organization (NEDO) Japan [grant number P03043]; and Grants-in-Aid for Scientific Research [grant number 16H00738 to H.M.] from the Japan Society for the Prom
-
Despite all efforts for development
2022-02-08

Despite all efforts for development of reliable laboratory methods, according to WHO/UNAIDS technical update on HIV incidence assays, none of the assays evaluated by Consortium for the Evaluation and Performance of HIV Incidence Assays (CEPHIA) have completely met the criteria for an incidence assay
-
Relative to the impact of moderate PAE on markers of
2022-02-08

Relative to the impact of moderate PAE on markers of histaminergic neurotransmission, there were four salient observations from the studies reported here. First, it does not appear that moderate PAE affects the number of HDC-positive neurons in the tuberomammillary nucleus of the ventral hypothalamu
-
Introduction Histamine H Imidazol yl
2022-02-08

Introduction Histamine (2-(1H-Imidazol-4-yl)ethanamine), mol.w. 111.15 g/mol belongs to biogenic amines, which arise in foodstuffs from amino acids by action of microorganism´s or tissue enzymes. Histamine (HA) is formed from the amino Vacuolin-1 L-histidine by action of enzyme histidine decarboxy
-
Based on our results we propose three possible mechanisms
2022-02-08

Based on our results, we propose three possible mechanisms of HER2 loss after trastuzumab-based therapy (Fig. 3). The first possibility is a result of the differential effects of treatments on clonal subsets. In breast cancer, such selective pressure has been suggested to preferentially eradicate HE
-
In conclusion re evaluation of HER status is necessary
2022-02-08

In conclusion, re-evaluation of HER2 status is necessary to determine the appropriate use of anti-HER2–targeted therapy beyond disease progression. EGFR and c-met amplification, as well as PIK3CA mutation, are rarely associated with acquired resistance. Our results highlight the importance of formal
-
RS testing has been extensively
2022-02-08

RS testing has been extensively validated in patients with early stage, ER+, HER2− patients. TAILORx, a randomized controlled trial to evaluate the role of adjuvant chemotherapy by RS, found no recurrence or survival benefit to the addition of chemotherapy to endocrine therapy in patients with inter
-
Camptothecin is a type of topo I inhibitor
2022-02-08

Camptothecin is a type of topo I inhibitor, and its prodrugs irinotecan and topotecan have been approved by the FDA for clinical cancer treatment. It has been reported that SAHA can enhance the cytotoxicity of camptothecin derivatives in several cancer cell lines20., 21., 22., 23., 24.. Taking the
-
Urinary hydroxypyrene OHP is a widely used biological marker
2022-02-08

Urinary 1-hydroxypyrene (1-OHP) is a widely used biological marker of exposure to PAHs and indicator for internal dose of activated PAHs (Jongeneelen, 1987, Adonis et al., 2003). PAH metabolites may be excreted either as free or as conjugated compounds. When 1-OHP is measured after treating the urin
-
Several previous reports have demonstrated that epithelial c
2022-02-08

Several previous reports have demonstrated that epithelial cell migration is important in promoting mucosal repair after damage caused by DSS and nonsteroidal anti-inflammatory drugs [33], [34], [35]. Cell migration is coordinated by many factors, including fibronectin and its receptor integrin α5,
-
Recently we suggested that KYNA an endogenous GPR agonist
2022-02-08

Recently, we suggested that KYNA – an endogenous GPR35 agonist could be produced in a human cornea since we showed the presence of the enzymes that catalyze the synthesis of KYNA – kynurenine aminotransferases I-III in corneal epithelium, stroma and endothelium (). Therefore, these findings provided
-
GLP is an intestinal peptide hormone that
2022-02-08

GLP-1 is an intestinal peptide hormone that is released by the gut following ingestion of food, particularly Sodium Aescinate mg and fats. Following its release, GLP-1 stimulates pancreatic β-cells to secrete insulin (Hirasawa et al., 2005, Covington et al., 2006). Originally, GLP-1 acted in a simi
15541 records 478/1037 page Previous Next First page 上5页 476477478479480 下5页 Last page